SCHEMBL71083

SCHEMBL71083

CC1(C)c2cc(Br)cnc2-c2ncc(Br)cc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.37
HTT P42858 2/20 0.37
KMT2A Q03164 1/20 0.37
DYRK1A Q13627 3/20 0.36
HSD17B10 Q99714 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
MAPK1 P28482 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
AKR1B1 P15121 1/20 0.31
AURKA O14965 1/20 0.31
DAPK3 O43293 1/20 0.31
JAK2 O60674 1/20 0.31
PRKD3 O94806 1/20 0.31
MAP4K4 O95819 1/20 0.31
PAK4 O96013 1/20 0.31
ABL1 P00519 1/20 0.31
NTRK1 P04629 1/20 0.31
FYN P06241 1/20 0.31
RET P07949 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL431223 0.86 PDK2 (0.33) SMN1; SMN2HTTKMT2ANPSR1
SCHEMBL15674426 0.83 BACE1 (0.33) SMN1; SMN2AKR1B1LTKKDRAURKB
SCHEMBL69252 0.82 PDE4B (0.37) SMN1; SMN2HTTKMT2AALDH1A1MAPT
SCHEMBL15705967 0.77 PLK4 (0.33) DYRK1AAURKAJAK2PRKD3MAP4K4
SCHEMBL17427089 0.77 PDK2 (0.36) KMT2A
SCHEMBL15705972 0.77 SMN1; SMN2 (0.34) SMN1; SMN2HTTKMT2ADYRK1AHSD17B10
SCHEMBL12306486 0.74 PDK2 (0.42) KMT2AKDM4E
SCHEMBL15674580 0.73 PLK4 (0.38) SMN1; SMN2DYRK1AAURKAJAK2PRKD3
SCHEMBL25029085 0.71 AKR1B1 (0.40) SMN1; SMN2DYRK1AHSD17B10AKR1B1AURKA
SCHEMBL29361404 0.71 AKR1B1 (0.40) SMN1; SMN2DYRK1AHSD17B10AKR1B1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129899-B1 Azafluorene derivative and organic light-emitting device using the derivative CANON KABUSHIKI KAISHA (JP) 2012-03-06 US disclosed
US-20120049176-A1 AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE CANON KABUSHIKI KAISHA (JP) 2012-03-01 US disclosed
US-8110685-B2 Efficient, durable electron transport layers; low driving voltage; simple, low cost production CANON KABUSHIKI KAISHA (JP) 2012-02-07 US disclosed
US-20080154040-A1 AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE CANON KABUSHIKI KAISHA (JP) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080154040-A1 AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE AZI2, CYP1A2, CYP2C19 SMN1; SMN2 4373/4885HTT 4747/4885KMT2A 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.